© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
This series highlights the evolving role of BTK inhibitors for the treatment of CLL.
April 27th 2021
Continued data for the first-generation BTK inhibitor have demonstrated its expanding utility amid a growing treatment arsenal.
May 6th 2021
With the treatment landscape rapidly developing with the approval of new agents and the investigation of various combination regimens, understanding the individual profiles of each agent will aid treatment selection.
May 13th 2021
Findings suggest that combination regimens may extend overall and progression-free survival.
May 20th 2021
Targeting different pathways may dramatically reduce the risk of resistance emergence and improve outcomes.
September 20th 2021
Paul M. Barr, MD discusses key takeaways from the follow-up data and reflects on the clinical and practical implications of the 7-year findings.
December 3rd 2021
Zanubrutinib has demonstrated clinical benefit as both a monotherapy and in combination with other agents for the treatment of patients with chronic lymphocytic leukemia.